Literature DB >> 14769202

Loss of C-terminal alpha-helix decreased SDF-1alpha-mediated signaling and chemotaxis without influencing CXCR4 internalization.

Shao-hui Cai1, Yi Tan, Xian-da Ren, Xiao-hong Li, Shao-xi Cai, Jun Du.   

Abstract

AIM: To investigate the possibility that a novel alpha-helix-defective mutant of stromal cell-derived factor-1alpha (SDF-1alpha) (SDF-1/54R) acts as an antagonist of CXC chemokine receptor 4 (CXCR4).
METHODS: According to the genetic sequence of natural SDF-1alpha, a recombinant alpha-helix-defective mutant of SDF-1alpha was designed and some biologic characteristics of this mutant were demonstrated. The migration of Jurkat cells was assessed with chemotactic assay. ERK phosphorylation was analyzed by Western blot with a specific anti-phospho-ERK1/2 antibody. Intracellular calcium influx was examined by flow cytometer with a calcium indicator dye Fluo-3AM. The CXCR4 on the cell surface was detected by flow cytometer with a PE conjoined anti-human CXCR4 antibody.
RESULTS: Compared with native SDF-1alpha, SDF-1/54R displayed apparent decrease in chemotactic ability, ERK1/2 activation, and intracellular calcium influx in Jurkat cells. However, the binding to CXCR4 and inducing CXCR4 internalization of SDF-1/54R did not change outstandingly. Moreover, a competitive inhibitory effect of SDF-1/54R on the migration of Jurkat cells induced by native SDF-1alpha was confirmed.
CONCLUSION: Alpha-helix-defective mutant of SDF-1alpha, SDF-1/54R that remained both the N-terminus and the central beta-sheet region, decreased SDF-1alpha-mediated signaling and chemotaxis but did not influence CXCR4 internalization, which suggested that SDF-1/54R might be developed as an anti-CHIV inhibitor with high biological potency and low side-effect.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14769202

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  6 in total

1.  Structural and functional basis of CXCL12 (stromal cell-derived factor-1 alpha) binding to heparin.

Authors:  James W Murphy; Yoonsang Cho; Aristidis Sachpatzidis; Chengpeng Fan; Michael E Hodsdon; Elias Lolis
Journal:  J Biol Chem       Date:  2007-01-29       Impact factor: 5.157

2.  Human β-defensin-3 structure motifs that are important in CXCR4 antagonism.

Authors:  Zhimin Feng; George R Dubyak; Xun Jia; Jacek T Lubkowski; Aaron Weinberg
Journal:  FEBS J       Date:  2013-06-07       Impact factor: 5.542

3.  Phenotypic Knockout of CXCR4 Expression by a Novel Intrakine Mutant hSDF-1α/54/KDEL Inhibits Breast Cancer Metastasis.

Authors:  Hong-Yuan Chen; Eric S Clayman; Wei-Feng Ma
Journal:  J Interferon Cytokine Res       Date:  2015-05-15       Impact factor: 2.607

4.  A novel CXCR4 antagonist derived from human SDF-1beta enhances angiogenesis in ischaemic mice.

Authors:  Yi Tan; Yan Li; Jian Xiao; Hongwei Shao; Chuanlin Ding; Gavin E Arteel; Keith A Webster; Jun Yan; Hong Yu; Lu Cai; Xiaokun Li
Journal:  Cardiovasc Res       Date:  2009-02-05       Impact factor: 10.787

Review 5.  CXCR4 in breast cancer: oncogenic role and therapeutic targeting.

Authors:  Chao Xu; Hong Zhao; Haitao Chen; Qinghua Yao
Journal:  Drug Des Devel Ther       Date:  2015-08-28       Impact factor: 4.162

6.  A Novel CXCR4 Targeting Protein SDF-1/54 as an HIV-1 Entry Inhibitor.

Authors:  Suiyi Tan; Wenjuan Li; Zhaofeng Li; Yujing Li; Jiangyan Luo; Liangzhentian Yu; Jie Yang; Mengjie Qiu; Hongyan Cheng; Wei Xu; Shibo Jiang; Lu Lu; Shuwen Liu; Weifeng Ma
Journal:  Viruses       Date:  2019-09-18       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.